Neurochemical imaging in schizophrenia

Current Topics in Behavioral Neurosciences

Volumn 4, Issue , 2010, Pages 215-242

  Urban, Nina ^a   Abi Dargham, Anissa ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Dopamine; Gammaamino butyric acid (GABA); Glutamate; Neurochemical imaging techniques; Occupancy; Serotonin

Indexed keywords

3 METHYLSPIPERONE C 11; 4 AMINOBUTYRIC ACID; ARIPIPRAZOLE; BENZAMIDE DERIVATIVE; CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; FLUMAZENIL C 11; GLUTAMIC ACID; HALOPERIDOL; IOLOPRIDE I 123; IOMAZENIL I 123; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RACLOPRIDE; RACLOPRIDE C 11; RADIOISOTOPE; RISPERIDONE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; TANDOSPIRONE; UNINDEXED DRUG; ZIPRASIDONE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; DOPAMINE RECEPTOR; SEROTONIN RECEPTOR;

DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; LOW DRUG DOSE; NEUROCHEMISTRY; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR DENSITY; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC TRANSMISSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BRAIN; METABOLISM; PATHOLOGY; SCINTISCANNING;

BRAIN; HUMANS; NEUROTRANSMITTER AGENTS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 79952254055     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2010_37     Document Type: Review

References (178)

1. Abi-Dargham A (2007) Alterations of serotonin transmission in schizophrenia. Int Rev Neurobiol 78:133-164
2. Abi-Dargham A, Laruelle M (2005) Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 20:15-27
3. Abi-Dargham A, Moore H (2003) Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 5:404-416
4. Abi-Dargham A, Laruelle M, Aghajanian GK, Charney D, Krystal J (1997) The role of serotonin in the pathophysiology and treatment of schizophrenia. J Neuropsychiatry Clin Neurosci 9:1-17
5. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155:761-767
6. Abi-Dargham A, Laruelle M, Krystal J (1999) No evidence of altered in vivo benzodiazepine receptor binding in schizophrenia. Neuropsychopharmacology 20:650-661
7. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M (2000) Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97:8104-8109
8. Abi-Dargham A, Mawlawi O, Lombardo I (2002) Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22:3708-3719
9. Abi-Dargham A, Kegeles LS, Zea-Ponce Y, Mawlawi O, Martinez D, Mitropoulou V, O'Flynn K, Koenigsberg HW, Van Heertum R, Cooper T, Laruelle M, Siever LJ (2004) Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol Psychiatry 55:1001-1006
10. Aghajanian GK, Marek GJ (2000) Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Brain Res Rev 31:302-312
11. Agid O, Mamo D, Ginovart N, Vitcu I, Wilson AA, Zipursky RB, Kapur S (2007) Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response-a double-blind PET study in schizophrenia. Neuropsychopharmacology 32:1209-1215
12. Anis NA, Berry SC, Burton NR, Lodge D (1983) The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methylaspartate. Br J Pharmacol 79:565-575
13. Arora RC, Meltzer HY (1991) Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients. J Neural Transm Gen Sect 85:19-29
14. Bantick RA, Montgomery AJ, Bench CJ, Choudhry T, Malek N, McKenna PJ, Quested DJ, Deakin JF, Grasby PM (2004a) A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment. J Psychopharmacol 18:346-354
15. Bantick RA, Rabiner EA, Hirani E, de Vries MH, Hume SP, Grasby PM (2004b) Occupancy of agonist drugs at the 5-HT1A receptor. Neuropsychopharmacology 29:847-859
16. Benes FM (2000) Emerging principles of altered neural circuitry in schizophrenia. Brain Res Brain Res Rev 31:251-269
17. Benes FM, Wickramasinghe R, Vincent SL, Khan Y, Todtenkopf M (1997) Uncoupling of GABA (A) and benzodiazepine receptor binding activity in the hippocampal formation of schizophrenic brain. Brain Res 755:121-129
18. Blin J, Baron JC, Cambon H, Bonnet AM, Dubois B, Loc'h C, Maziere B, Agid Y (1989) Striatal dopamine D2 receptors in tardive dyskinesia: PET study. J Neurol Neurosurg Psychiatry 52:1248-1252
19. Borg J (2008) Molecular imaging of the 5-HT(1A) receptor in relation to human cognition. Behav Brain Res 195:103-111
20. BozarthMA(1986) Neural basis of psychomotor stimulant and opiate reward: evidence suggesting the involvement of a common dopaminergic system. Behav Brain Res 22:107-116
21. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94:2569-2574
22. Bressan RA, Erlandsson K, Jones HM, Mulligan RS, Ell PJ, Pilowsky LS (2003) Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study. J Clin Psychopharmacol 23:5-14
23. Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi B, Mantil J, Kemether E, Oakes TR, Mukherjee J (2006) D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res 85:232-244
24. Burnet PW, Eastwood SL, Harrison PJ (1996) 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 15:442-455
25. Busatto GF, Pilowsky LS (1995) Neuroreceptor mapping with in-vivo imaging techniques: principles and applications. Br J Hosp Med 53:309-313
26. Busatto GF, Pilowsky LS, Costa DC, Ell PJ, David AS, Lucey JV, Kerwin RW (1997) Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. Am J Psychiatry 154:56-63
27. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, Seidman LJ, Perkins D, Tsuang M, McGlashan T, Heinssen R (2008) Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 65:28-37
28. Catafau AM, Corripio I, Perez V, Martin JC, Schotte A, Carrio I, Alvarez E (2006) Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response. Psychiatry Res 148:175-183
29. Crawley JC, Crow TJ, Johnstone EC, Oldland SR, Owen F, Owens DG, Smith T, Veall N, Zanelli GD (1986) Uptake of 77Br-spiperone in the striata of schizophrenic patients and controls. Nucl Med Commun 7:599-607
30. Cropley VL, Fujita M, Innis RB, Nathan PJ (2006) Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol Psychiatry 59:898-907
31. Cruz DA, Eggan SM, Azmitia EC, Lewis DA (2004) Serotonin1A receptors at the axon initial segment of prefrontal pyramidal neurons in schizophrenia. Am J Psychiatry 161:739-742
32. Dao-Castellana MH, Paillere-Martinot ML, Hantraye P, Attar-Levy D, Remy P, Crouzel C, Artiges E, Feline A, Syrota A, Martinot JL (1997) Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res 23:167-174
33. Dean B, Hayes W (1996) Decreased frontal cortical serotonin2A receptors in schizophrenia. Schizophr Res 21:133-139
34. Ekelund J, Slifstein M, Narendran R, Guillin O, Belani H, Guo NN, Hwang Y, Hwang DR, Abi-Dargham A, LaruelleM(2007) In vivo DA D(1) receptor selectivity of NNC 112 and SCH 23390. Mol Imaging Biol 9:117-125
35. Elkashef AM, Doudet D, Bryant T, Cohen RM, Li SH, Wyatt RJ (2000) 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res 100:1-11
36. Erritzoe D, Rasmussen H, Kristiansen KT, Frokjaer VG, Haugbol S, Pinborg L, Baare W, Svarer C, Madsen J, Lublin H, Knudsen GM, Glenthoj BY (2008) Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients. Neuropsychopharmacology 33:2435-2441
37. Farde L, Wiesel FA, Stone-Elander S, Halldin C, Nordstrom AL, Hall H, Sedvall G (1990) D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiatry 47:213-219
38. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544
39. Frankle WG (2007) Neuroreceptor imaging studies in schizophrenia. Harv Rev Psychiatry 15:212-232
40. Frankle WG, Laruelle M (2002) Neuroreceptor imaging in psychiatric disorders. Ann Nucl Med 16:437-446
41. Frankle WG, Gil R, Hackett E, Mawlawi O, Zea-Ponce Y, Zhu Z, Kochan LD, Cangiano C, Slifstein M, Gorman JM, Laruelle M, Abi-Dargham A (2004a) Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications. Psychopharmacology (Berl) 175:473-480
42. Frankle WG, Huang Y, Hwang DR, Talbot PS, Slifstein M, Van Heertum R, Abi-Dargham A, Laruelle M (2004b) Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. J Nucl Med 45:682-694
43. Frankle WG, Narendran R, Huang Y, Hwang DR, Lombardo I, Cangiano C, Gil R, Laruelle M, Abi-Dargham A (2005) Serotonin transporter availability in patients with schizophrenia: a positron emission tomography imaging study with [11C]DASB. Biol Psychiatry 57: 1510-1516
44. Frankle WG, Lombardo I, Kegeles LS, Slifstein M, Martin JH, Huang Y, Hwang DR, Reich E, Cangiano C, Gil R, Laruelle M, Abi-Dargham A (2006) Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635. Psychopharmacology (Berl) 189:155-164
45. Frankle WG, Cho RY, Narendran R, Mason NS, Vora S, Litschge M, Price JC, Lewis DA, Mathis CA (2009) Tiagabine increases [11C]flumazenil binding in cortical brain regions in healthy control subjects. Neuropsychopharmacology 34:624-633
46. Fujita M, Verhoeff NP, Varrone A, Zoghbi SS, Baldwin RM, Jatlow PA, Anderson GM, Seibyl JP, Innis RB (2000) Imaging extrastriatal dopamine D(2) receptor occupancy by endogenous dopamine in healthy humans. Eur J Pharmacol 387:179-188
47. Gaddum JH (1957) Serotonin-LSD interactions. Ann NY Acad Sci 66:643-647, discussion 647-648
48. Ginovart N (2005) Imaging the dopamine system with in vivo [11C]raclopride displacement studies: understanding the true mechanism. Mol Imaging Biol 7:45-52
49. Glenthoj BY, Mackeprang T, Svarer C, Rasmussen H, Pinborg LH, Friberg L, Baare W, Hemmingsen R, Videbaek C (2006) Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biol Psychiatry 60:621-629
50. Goldman-Rakic PS, Selemon LD (1997) Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull 23:437-458
51. Grunder G, Fellows C, Janouschek H, Veselinovic T, Boy C, Brocheler A, Kirschbaum KM, Hellmann S, Spreckelmeyer KM, Hiemke C, Rosch F, Schaefer WM, Vernaleken I (2008) Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F] fallypride PET study. Am J Psychiatry 165:988-995
52. Guillin O, Abi-Dargham A, Laruelle M (2007) Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol 78:1-39
53. Guo N, Hwang DR, Lo ES, Huang YY, Laruelle M, Abi-Dargham A (2003) Dopamine depletion and in vivo binding of PET D1 receptor radioligands: implications for imaging studies in schizophrenia. Neuropsychopharmacology 28:1703-1711
54. Gurevich EV, Joyce JN (1997) Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol Psychiatry 42:529-545
55. Hall H, Sedvall G, Magnusson O, Kopp J, Halldin C, Farde L (1994) Distribution of D1-and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 11:245-256
56. Halldin C, Farde L, Hogberg T, Mohell N, Hall H, Suhara T, Karlsson P, Nakashima Y, Swahn CG (1995) Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 36:1275-1281
57. Hashimoto T, Nishino N, Nakai H, Tanaka C (1991) Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci 48:355-363
58. Heinz A, Knable MB, Weinberger DR (1996) Dopamine D2 receptor imaging and neuroleptic drug response. J Clin Psychiatry 57(Suppl 11):84-88, discussion 89-93
59. Hietala J, Syvalahti E, Vuorio K, Nagren K, Lehikoinen P, Ruotsalainen U, Rakkolainen V, Lehtinen V, Wegelius U (1994) Striatal D2 dopamine receptor characteristics in neurolepticnaive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 51:116-123
60. Hietala J, Syvalahti E, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, Solin O, Kuoppamaki M, Kirvela O, Ruotsalainen U, Salokangas RKR (1995) Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 346:1130-1131
61. Hietala J, Syvalahti E, Vilkman H, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, Solin O, Kuoppamaki M, Eronen E, Ruotsalainen U, Salokangas RK (1999) Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr Res 35:41-50
62. Hirvonen J, van Erp TG, Huttunen J, Aalto S, Nagren K, Huttunen M, Lönnqvist J, Kaprio J, Hietala J, Cannon TD (2005) Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch Gen Psychiatry 4:371-378
63. Hirvonen J, van Erp TG, Huttunen J, Aalto S, Nagren K, Huttunen M, Lonnqvist J, Kaprio J, Cannon TD, Hietala J (2006) Brain dopamine d1 receptors in twins discordant for schizophrenia. Am J Psychiatry 163:1747-1753
64. Howes OD, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull 35:549-562
65. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Grasby PM, McGuire PK (2007) Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br J Psychiatry 51(Suppl):S13-S18
66. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, Bramon-Bosch E, Valmaggia L, Johns L, Broome M, McGuire PK, Grasby PM (2009) Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 66:13-20
67. Hsiao MC, Lin KJ, Liu CY, Tzen KY, Yen TC (2003) Dopamine transporter change in drug-naive schizophrenia: an imaging study with 99mTc-TRODAT-1. Schizophr Res 65:39-46
68. Huang Y, Hwang DR, Narendran R, Sudo Y, Chatterjee R, Bae SA, Mawlawi O, Kegeles LS, Wilson AA, Kung HF, Laruelle M (2002) Comparative evaluation in nonhuman primates of five PET radiotracers for imaging the serotonin transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFM. J Cereb Blood Flow Metab 22:1377-1398
69. Huttunen J, Heinimaa M, Svirskis T, Nyman M, Kajander J, Forsback S, Solin O, Ilonen T, Korkeila J, Ristkari T, McGlashan T, Salokangas RK, Hietala J (2008) Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia. Biol Psychiatry 63:114-117
70. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533-1539
71. Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE (1993) Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 8:315-336
72. Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 3:360-369
73. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S (1998) 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155:921-928
74. Kapur S, Zipursky RB, Remington G (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156:286-293
75. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 4:514-520
76. Karlsson P, Smith L, Farde L, Harnryd C, Sedvall G, Wiesel FA (1995) Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology (Berl) 121:309-316
77. Karlsson P, Farde L, Halldin C, Sedvall G (2002) PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 159:761-767
78. Kasper S, Tauscher J, Kufferle B, Barnas C, Pezawas L, Quiner S (1999) Dopamine-and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia. Eur Arch Psychiatry Clin Neurosci 249(Suppl 4):83-89
79. Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae SA, Gonzales R, Kim JH, Alvarez B, Gil R, Laruelle M, Abi-Dargham A (2008) Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology 33:3111-3125
80. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY (2005) Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol. Neuropsychopharmacology 30:2283-2289
81. Kessler RM, Woodward ND, Riccardi P, Li R, Ansari MS, Anderson S, Dawant B, Zald D, Meltzer HY (2009) Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol Psychiatry 65:1024-1031
82. Kestler LP, Walker E, Vega EM (2001) Dopamine receptors in the brains of schizophrenia patients: a meta-analysis of the findings. Behav Pharmacol 12:355-371
83. Knable MB, Heinz A, Raedler T, Weinberger DR (1997a) Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. Psychiatry Res 75:91-101
84. Knable MB, Egan MF, Heinz A, Gorey J, Lee KS, Coppola R, Weinberger DR (1997b) Altered dopaminergic function and negative symptoms in drug-free patients with schizophrenia. [123I]-iodobenzamide SPECT study. Br J Psychiatry 171:574-577
85. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214
86. Laakso A, Vilkman H, Alakare B, Haaparanta M, Bergman J, Solin O, Peurasaari J, Rakkolainen V, Syvalahti E, Hietala J (2000) Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. Am J Psychiatry 157:269-271
87. Laakso A, Bergman J, Haaparanta M, Vilkman H, Solin O, Syvalahti E, Hietala J (2001) Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr Res 52:115-120
88. Laruelle M (1998) Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 42:211-221
89. Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423-451
90. Laruelle M, Abi-Dargham A, Casanova MF, Toti R, Weinberger DR, Kleinman JE (1993) Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch Gen Psychiatry 50:810-818
91. Laruelle M, Wallace E, Seibyl JP, Baldwin RM, Zea-Ponce Y, Zoghbi SS, Neumeyer JL, Charney DS, Hoffer PB, Innis RB (1994) Graphical, kinetic, and equilibrium analyses of in vivo [123I] beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 14:982-994
92. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB (1996) Single photon emission computerized tomography imaging of amphetamineinduced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93:9235-9240
93. Laruelle M, Iyer RN, al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, Baldwin RM, Kung HF, Charney DS, Hoffer PB, Innis RB, Bradberry CW (1997) Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25:1-14
94. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R (1999) Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 46:56-72
95. Laruelle M, Abi-Dargham A, van Dyck C (2000) Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. Biol Psychiatry 47:371-379
96. Laruelle M, Frankle WG, Narendran R, Kegeles LS, Abi-Dargham A (2005) Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Clin Ther 27(Suppl A):S16-S24
97. Lavalaye J, Linszen DH, Booij J, Dingemans PM, Reneman L, Habraken JB, Gersons BP, van Royen EA (2001) Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT. Schizophr Res 47:59-67
98. Leff P (1995) The two-state model of receptor activation. Trends Pharmacol Sci 16:89-97
99. Leucht S, Busch R, Hamann J, Kissling W, Kane JM (2005) Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 57: 1543-1549
100. Lewis DA (2000) GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia. Brain Res Brain Res Rev 31:270-276
101. Lewis R, Kapur S, Jones C, DaSilva J, Brown GM, Wilson AA, Houle S, Zipursky RB (1999) Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects. Am J Psychiatry 156:72-78
102. Lieberman JA, Alvir J, Geisler S, Ramos-Lorenzi J, Woerner M, Novacenko H, Cooper T, Kane JM (1994) Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia. Neuropsychopharmacology 11:107-118
103. Lindstrom LH, Gefvert O, Hagberg G, Lundberg T, Bergstrom M, Hartvig P, Langstrom B (1999) Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry 46:681-688
104. Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G (2004) A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 161:818-825
105. Mamo D, Graff A, Romeyer F et al (2006) Central D2 and 5HT2A occupancy of aripiprazole in patients with schizophrenia. Schizophr Res 82:104-105
106. Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S (2007) Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry 164:1411-1417
107. Martinot JL, Peron-Magnan P, Huret JD, Mazoyer B, Baron JC, Boulenger JP, Loc'h C, Maziere B, Caillard V, Loo H, Syrota A (1990) Striatal D2 dopaminergic receptors assessed with positron emission tomography and [76Br]bromospiperone in untreated schizophrenic patients. Am J Psychiatry 147:44-50
108. Martinot JL, Paillere-Martinot ML, Loc'h C, Hardy P, Poirier MF, Mazoyer B, Beaufils B, Maziere B, Allilaire JF, Syrota A (1991) The estimated density of D2 striatal receptors in schizophrenia. A study with positron emission tomography and 76Br-bromolisuride. Br J Psychiatry 158:346-350
109. Martinot JL, Paillere-Martinot ML, Loc'h C, Lecrubier Y, Dao-Castellana MH, Aubin F, Allilaire JF, Mazoyer B, Maziere B, Syrota A (1994) Central D2 receptors and negative symptoms of schizophrenia. Br J Psychiatry 164:27-34
110. Mateos JJ, Lomena F, Parellada E, Mireia F, Fernandez-Egea E, Pavia J, Prats A, Pons F, Bernardo M (2007) Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. Psychopharmacology (Berl) 191:805-811
111. McGowan S, Lawrence AD, Sales T, Quested D, Grasby P (2004) Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch Gen Psychiatry 61:134-142
112. Meltzer HY, Sumiyoshi T (2008) Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? Behav Brain Res 195:98-102
113. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27:1159-1172
114. Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, Weinberger DR, Berman KF (2002) Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 5:267-271
115. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ (1984) A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 15:217-227
116. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78:189-225
117. Mizrahi R, Rusjan P, Agid O, Graff A, Mamo DC, Zipursky RB, Kapur S (2007) Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am J Psychiatry 164:543-546
118. Moore RY, Whone AL, McGowan S, Brooks DJ (2003) Monoamine neuron innervation of the normal human brain: an 18F-DOPA PET study. Brain Res 982:137-145
119. Ngan ET, Yatham LN, Ruth TJ, Liddle PF (2000) Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: a PET study using [(18)F]setoperone. Am J Psychiatry 157:1016-1018
120. Nordstrom AL, Farde L, Halldin C (1993a) High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology (Berl) 110:365-367
121. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G (1993b) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227-235
122. Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G (1995a) D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152:1444-1449
123. Nordstrom FL, Eriksson L, Halldin C (1995b) No elevated D2 dopamine receptors in neurolepticnaive schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone. Psychiatry Res 61:67-83
124. Nyberg S, Nilsson U, Okubo Y, Halldin C, Farde L (1998) Implications of brain imaging for the management of schizophrenia. Int Clin Psychopharmacol 13(Suppl 3):S15-S20
125. Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L (1999) Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 156:869-875
126. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M (1997) Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385:634-636
127. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M (2000) Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography. Life Sci 66:2455-2464
128. Olney JW, Farber NB (1995) NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 13:335-345
129. Parellada E, Lomena F, Catafau AM, Bernardo M, Font M, Fernandez-Egea E, Pavia J, Gutierrez F (2004) Lack of sex differences in striatal dopamine D2 receptor binding in drug-naive schizophrenic patients: an IBZM-SPECT study. Psychiatry Res 130:79-84
130. Pearlson GD, Tune LE, Wong DF, Aylward EH, Barta PE, Powers RE, Tien AY, Chase GA, Harris GJ, Rabins PV (1993) Quantitative D2 dopamine receptor PET and structural MRI changes in late-onset schizophrenia. Schizophr Bull 19:783-795
131. Pilowsky LS, Bressan RA, Stone JM, Erlandsson K, Mulligan RS, Krystal JH, Ell PJ (2006) First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry 11:118-119
132. Raedler TJ, Knable MB, Lafargue T, Urbina RA, Egan MF, Pickar D, Weinberger DR (1999) In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine. Psychiatry Res 90:81-90
133. Rousset OG, Ma Y, Evans AC (1998) Correction for partial volume effects in PET: principle and validation. J Nucl Med 39:904-911
134. Rousset OG, Collins DL, Rahmim A, Wong DF (2008) Design and implementation of an automated partial volume correction in PET: application to dopamine receptor quantification in the normal human striatum. J Nucl Med 49:1097-1106
135. Schmitt GJ, Meisenzahl EM, Frodl T, La Fougere C, Hahn K, Moller HJ, Dresel S (2005) The striatal dopamine transporter in first-episode, drug-naive schizophrenic patients: evaluation by the new SPECT-ligand[99mTc]TRODAT-1. J Psychopharmacol 19:488-493
136. Schmitt GJ, la Fougere C, Dresel S, Frodl T, Hahn K, Moller HJ, Meisenzahl EM (2008) Dualisotope SPECT imaging of striatal dopamine: first episode, drug naive schizophrenic patients. Schizophr Res 101:133-141
137. Sedvall G (1990) Monoamines and schizophrenia. Acta Psychiatr Scand 358(Suppl):7-13
138. Seeman MV, Seeman P (1988) Psychosis and positron tomography. Can J Psychiatry 33:299-306
139. Seeman P, Bzowej NH, Guan HC, Bergeron C, Reynolds GP, Bird ED, Riederer P, Jellinger K, Tourtellotte WW (1987) Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology 1:5-15
140. Sjoholm H, Bratlid T, Sundsfjord J (2004) 123I-beta-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia. Psychopharmacology (Berl) 173:27-31
141. Slifstein M, Laruelle M (2001) Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl Med Biol 28:595-608
142. Slifstein M, Hwang DR, Huang Y, Guo N, Sudo Y, Narendran R, Talbot P, Laruelle M (2004) In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates. Psychopharmacology (Berl) 175:274-286
143. Slifstein M, Kegeles LS, Gonzales R, Frankle WG, Xu X, Laruelle M, Abi-Dargham A (2007) [(11)C]NNC 112 selectivity for dopamine D(1) and serotonin 5-HT(2A) receptors: a PET study in healthy human subjects. J Cereb Blood Flow Metab 27:1733-1741
144. Stone JM, Pilowsky LS (2007) Novel targets for drugs in schizophrenia. CNS Neurol Disord Drug Targets 6:265-272
145. Suhara T, Okubo Y, Yasuno F, Sudo Y, Inoue M, Ichimiya T, Nakashima Y, Nakayama K, Tanada S, Suzuki K, Halldin C, Farde L (2002) Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry 59:25-30
146. Sumiyoshi T, Stockmeier CA, Overholser JC, Dilley GE, Meltzer HY (1996) Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res 708:209-214
147. Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C, Jayathilake K, Meltzer HY (2001a) Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 158:1722-1725
148. Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Kurachi M, Uehara T, Sumiyoshi S, Sumiyoshi C, Meltzer HY (2001b) The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol Psychiatry 49:861-868
149. Takahashi H, Higuchi M, Suhara T (2006) The role of extrastriatal dopamine D2 receptors in schizophrenia. Biol Psychiatry 59:919-928
150. Takano A, Suhara T, Kusumi I, Takahashi Y, Asai Y, Yasuno F, Ichimiya T, Inoue M, Sudo Y, Koyama T (2006) Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations. Prog Neuropsychopharmacol Biol Psychiatry 30:75-81
151. Talvik M, Nordstrom AL, Olsson H, Halldin C, Farde L (2003) Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. Int J Neuropsychopharmacol 6:361-370
152. Talvik M, Nordstrom AL, Okubo Y, Olsson H, Borg J, Halldin C, Farde L (2006) Dopamine D2 receptor binding in drug-naive patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Res 148:165-173
153. Tamminga CA (2006) The neurobiology of cognition in schizophrenia. J Clin Psychiatry 67:e11
154. Tauscher J, Kapur S, Verhoeff NP, Hussey DF, Daskalakis ZJ, Tauscher-Wisniewski S, Wilson AA, Houle S, Kasper S, Zipursky RB (2002) Brain serotonin 5-HT1A receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychiatry 59:514-520
155. Tauscher J, Hussain T, Agid O, Verhoeff NP, Wilson AA, Houle S, Remington G, Zipursky RB, Kapur S (2004) Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry 161:1620-1625
156. Tauscher-Wisniewski S, Kapur S, Tauscher J, Jones C, Daskalakis ZJ, Papatheodorou G, Epstein I, Christensen BK, Zipursky RB (2002) Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry 63:992-997
157. Taylor SF, Koeppe RA, Tandon R, Zubieta JK, Frey KA (2000) In vivo measurement of the vesicular monoamine transporter in schizophrenia. Neuropsychopharmacology 23: 667-675
158. TownsendDW(2004) Physical principles and technology of clinical PET imaging. Ann Acad Med Singapore 33:133-145
159. Trichard C, Paillere-Martinot ML, Attar-Levy D, Blin J, Feline A, Martinot JL (1998) No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Schizophr Res 31:13-17
160. Tune LE, Wong DF, Pearlson G, Strauss M, Young T, Shaya EK, Dannals RF, Wilson AA, Ravert HT, Sapp J, Cooper T, Chase GA, Wagner HN Jr (1993) Dopamine D2 receptor density estimates in schizophrenia: a positron emission tomography study with 11C-N-methylspiperone. Psychiatry Res 49:219-237
161. Tune L, Barta P, Wong D, Powers RE, Pearlson G, Tien AY, Wagner HN (1996) Striatal dopamine D2 receptor quantification and superior temporal gyrus: volume determination in 14 chronic schizophrenic subjects. Psychiatry Res 67:155-158
162. Tuppurainen H, Kuikka J, Viinamaki H, Husso-Saastamoinen M, Bergstrom K, Tiihonen J (2003) Extrastriatal dopamine D 2/3 receptor density and distribution in drug-naive schizophrenic patients. Mol Psychiatry 8:453-455
163. Ugedo L, Grenhoff J, Svensson TH (1989) Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology (Berl) 98:45-50
164. van Berckel BN, Kegeles LS, Waterhouse R, Guo N, Hwang DR, Huang Y, Narendran R, Van Heertum R, Laruelle M (2006) Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography. Neuropsychopharmacology 31:967-977
165. Verhoeff NP, Soares JC, D'Souza CD, Gil R, Degen K, Abi-Dargham A, Zoghbi SS, Fujita M, Rajeevan N, Seibyl JP, Krystal JH, van Dyck CH, Charney DS, Innis RB (1999) [123I] Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. Psychiatry Res 91:163-173
166. Vernaleken I, Fellows C, Janouschek H, Brocheler A, Veselinovic T, Landvogt C, Boy C, Buchholz HG, Spreckelmeyer K, Bartenstein P, Cumming P, Hiemke C, Rosch F, Schafer W, Wong DF, Grunder G (2008) Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]fallypride and [11C] raclopride (D2/D3-receptor occupancy of ziprasidone). J Clin Psychopharmacol 28:608-617
167. Vollenweider FX, Geyer MA (2001) A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull 56:495-507
168. Vollenweider FX, Vontobel P, Oye I, Hell D, Leenders KL (2000) Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. J Psychiatr Res 34:35-43
169. Waterhouse RN (2003) Imaging the PCP site of the NMDA ion channel. Nucl Med Biol 30:869-878
170. Weinberger DR, Laurelle M (2001) Neurochemical and neuropharmacological imaging in schizophrenia. In: Davis KL, Charney DS, Coyle JT, Nemeroff C (eds) Neuropharmacology-the fifth generation of progress. Lippincott Williams & Wilkins, Philadelphia, pp 833-856
171. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue CY, Cooper TB, Brodie JD (1989) Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 146:905-908
172. Wong DF, Wagner HN Jr, Tune LE, Dannals RF, Pearlson GD, Links JM, Tamminga CA, Broussolle EP, Ravert HT, Wilson AA, Toung JK, Malat J, Williams JA, O'Tuama LA, Snyder SH, Kuhar MJ, Gjedde A (1986) Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 234:1558-1563
173. Xiberas X, Martinot JL, Mallet L, Artiges E, Loc HC, Maziere B, Paillere-Martinot ML (2001) Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 179:503-508
174. Yang YK, Yu L, Yeh TL, Chiu NT, Chen PS, Lee IH (2004) Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study. Am J Psychiatry 161:1496-1498
175. Yasuno F, Suhara T, Ichimiya T, Takano A, Ando T, Okubo Y (2004a) Decreased 5-HT1A receptor binding in amygdala of schizophrenia. Biol Psychiatry 55:439-444
176. Yasuno F, Suhara T, Okubo Y, Sudo Y, Inoue M, Ichimiya T, Takano A, Nakayama K, Halldin C, Farde L (2004b) Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia. Am J Psychiatry 161:1016-1022
177. Yoder KK, Hutchins GD, Morris ED, Brashear A, Wang C, Shekhar A (2004) Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia. Schizophr Res 71:371-375
178. Zakzanis KK, Hansen KT (1998) Dopamine D2 densities and the schizophrenic brain. Schizophr Res 32:201-206